{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T18:18:24Z","timestamp":1781374704065,"version":"3.54.1"},"reference-count":54,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T00:00:00Z","timestamp":1592870400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2020.01531","type":"journal-article","created":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T07:39:20Z","timestamp":1592897960000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":33,"title":["Nanobodies: Prospects of Expanding the Gamut of Neutralizing Antibodies Against the Novel Coronavirus, SARS-CoV-2"],"prefix":"10.3389","volume":"11","author":[{"given":"Rocktotpal","family":"Konwarh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,6,23]]},"reference":[{"key":"B1","unstructured":"WHO Coronavirus Disease (COVID-19) Dashboard2020"},{"key":"B2","doi-asserted-by":"publisher","first-page":"m1375","DOI":"10.1136\/bmj.m1375","article-title":"COVID-19: four fifths of cases are asymptomatic, China figures indicate","volume":"369","author":"Day","year":"2020","journal-title":"BMJ"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1056\/NEJMe2009758","article-title":"Asymptomatic transmission, the Achilles' heel of current strategies to control COVID-19","volume":"382","author":"Gandhi","year":"2020","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.7326\/M20-2003","article-title":"Autopsy findings and venous thromboembolism in patients with COVID-19: A prospective cohort study","author":"Wichmann","year":"2020","journal-title":"Ann Intern Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/j.cell.2020.04.004","article-title":"Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2","volume":"181","author":"Monteil","year":"2020","journal-title":"Cell."},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.31219\/osf.io\/6eagn","article-title":"Landscape coronavirus disease 2019 test (COVID-19 test) in vitro- A comparison of PCR vs Immunoassay vs CRISPR-based test","author":"Bai","year":"2020","journal-title":"OSF [Preprints]."},{"key":"B7","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.jpha.2020.02.010","article-title":"Recent advances and perspectives of nucleic acid detection for coronavirus","volume":"10","author":"Shen","year":"2020","journal-title":"J Pharm Anal"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e00483","DOI":"10.1128\/AAC.00483-20","article-title":"Updated approaches against SARS-CoV-2","volume":"64","author":"Li","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"B9","unstructured":"PerperR\n          Israel's Government Research Agency Says it Successfully Isolated a Key Coronavirus Antibody, Paving the Way for a Possible Breakthrough Treatment2020"},{"key":"B10","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.it.2020.03.007","article-title":"Neutralizing antibodies against SARS-CoV-2 and other human coronaviruses","volume":"41","author":"Jiang","year":"2020","journal-title":"Trends Immunol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.3389\/fimmu.2017.01603","article-title":"Nanobodies and nanobody-based human heavy chain antibodies as antitumor therapeutics","volume":"8","author":"Bannas","year":"2017","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1101\/2020.03.30.015990","article-title":"Identification of human single-domain antibodies against SARS-CoV-2","volume":"27","author":"Wu","year":"2020","journal-title":"Cell Host Microbe."},{"key":"B13","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","article-title":"Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein","volume":"181","author":"Walls","year":"2020","journal-title":"Cell"},{"key":"B14","doi-asserted-by":"publisher","first-page":"60","DOI":"10.3390\/v11010060","article-title":"Advances in MERS-CoV vaccines and therapeutics based on the receptor-binding domain","volume":"11","author":"Zhou","year":"2019","journal-title":"Viruses"},{"key":"B15","doi-asserted-by":"publisher","first-page":"12123","DOI":"10.1073\/pnas.0701000104","article-title":"Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies","volume":"104","author":"Zhu","year":"2007","journal-title":"PNAS."},{"key":"B16","doi-asserted-by":"publisher","first-page":"3220","DOI":"10.1128\/JVI.02377-07","article-title":"Structural basis for potent cross-neutralizing human monoclonal antibody protection against lethal human and zoonotic severe acute respiratory syndrome coronavirus challenge","volume":"82","author":"Rockx","year":"2008","journal-title":"J Virol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2536","DOI":"10.1073\/pnas.0307140101","article-title":"Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association","volume":"101","author":"Sui","year":"2004","journal-title":"PNAS."},{"key":"B18","doi-asserted-by":"publisher","first-page":"6085","DOI":"10.4049\/jimmunol.176.10.6085","article-title":"Cross-neutralization of human and palm civet severe acute respiratory syndrome coronaviruses by antibodies targeting the receptor-binding domain of spike protein","volume":"176","author":"He","year":"2006","journal-title":"J Immunol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1080\/22221751.2020.1729069","article-title":"Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody","volume":"9","author":"Tian","year":"2020","journal-title":"Emerg Microbes Infect"},{"key":"B20","doi-asserted-by":"publisher","first-page":"34610","DOI":"10.1074\/jbc.M603275200","article-title":"Structural basis of neutralization by a human anti-severe acute respiratory syndrome spike protein antibody, 80R","volume":"281","author":"Hwang","year":"2006","journal-title":"J Biol Chem."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/j.cell.2018.12.028","article-title":"Unexpected receptor functional mimicry elucidates activation of coronavirus fusion","volume":"176","author":"Walls","year":"2019","journal-title":"Cell."},{"key":"B22","doi-asserted-by":"publisher","first-page":"e02002","DOI":"10.1128\/JVI.02002-17","article-title":"Importance of neutralizing monoclonal antibodies targeting multiple antigenic sites on the Middle East respiratory syndrome coronavirus spike glycoprotein to avoid neutralization escape","volume":"92","author":"Wang","year":"2018","journal-title":"J Virol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1101\/2020.03.13.991570","article-title":"A highly conserved cryptic epitope in the receptor-binding domains of SARS-CoV-2 and SARS-CoV","volume":"368","author":"Yuan","year":"2020","journal-title":"Science"},{"key":"B24","doi-asserted-by":"publisher","first-page":"495","DOI":"10.3389\/fmicb.2017.00495","article-title":"Antibody engineering for pursuing a healthier future","volume":"8","author":"Saeed","year":"2017","journal-title":"Front. Microbiol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/363446a0","article-title":"Naturally occurring antibodies devoid of light chains","volume":"363","author":"Hamers-Casterman","year":"1993","journal-title":"Nature."},{"key":"B26","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1146\/annurev-biochem-063011-092449","article-title":"Nanobodies: natural single-domain antibodies","volume":"82","author":"Muyldermans","year":"2013","journal-title":"Annu Rev Biochem."},{"key":"B27","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.tibtech.2014.03.001","article-title":"Nanobody-based products as research and diagnostic tools","volume":"32","author":"De Meyer","year":"2014","journal-title":"Trends Biotechnol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.drudis.2016.04.003","article-title":"Nanobodies as therapeutics: big opportunities for small antibodies","volume":"21","author":"Steeland","year":"2016","journal-title":"Drug Discov Today"},{"key":"B29","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s40259-019-00392-z","article-title":"The therapeutic potential of nanobodies","volume":"34","author":"Jov\u010devska","year":"2019","journal-title":"BioDrugs"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/antib8010001","article-title":"Single-domain antibodies and their formatting to combat viral infections","volume":"8","author":"De Vlieger","year":"2019","journal-title":"Antibodies"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1074\/jbc.M111.242818","article-title":"Dual beneficial effect of interloop disulfide bond for single domain antibody fragments","volume":"287","author":"Govaert","year":"2012","journal-title":"J Biol Chem."},{"key":"B32","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1126\/science.aaq0620","article-title":"Universal protection against influenza infection by a multidomain antibody to influenza hemagglutinin","volume":"362","author":"Laursen","year":"2018","journal-title":"Science."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1016\/j.drudis.2018.06.003","article-title":"Therapeutic application of antibody fragments in autoimmune diseases: Current state and prospects","volume":"23","author":"Fernandes","year":"2018","journal-title":"Drug Discov Today"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1101\/2020.03.26.010165","article-title":"Structural basis for potent neutralization of betacoronaviruses by single-domain camelid antibodies","volume":"181","author":"Wrapp","year":"2020","journal-title":"Cell"},{"key":"B35","doi-asserted-by":"publisher","first-page":"195","DOI":"10.2217\/fvl-2019-0167","article-title":"Nanobodies: a new approach for the diagnosis and treatment of viral infectious diseases","volume":"15","author":"Sroga","year":"2020","journal-title":"Future Virol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"95263","DOI":"10.1371\/journal.pone.0095263","article-title":"Development of VHH antibodies against dengue virus type 2 NS1 and comparison with monoclonal antibodies for use in immunological diagnosis","volume":"9","author":"Fatima","year":"2014","journal-title":"PLoS ONE."},{"key":"B37","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1002\/hep.26430","article-title":"An alpaca nanobody inhibits hepatitis C virus entry and cell-to-cell transmission","volume":"58","author":"Tarr","year":"2013","journal-title":"Hepatol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.antiviral.2010.05.012","article-title":"In vitro antiviral activity of single domain antibody fragments against poliovirus","volume":"87","author":"Thys","year":"2010","journal-title":"Antivir Res"},{"key":"B39","doi-asserted-by":"publisher","first-page":"e1006636","DOI":"10.1371\/journal.ppat.1006636","article-title":"Nanobodies targeting norovirus capsid reveal functional epitopes and potential mechanisms of neutralization","volume":"13","author":"Koromyslova","year":"2017","journal-title":"PLoS Pathog"},{"key":"B40","doi-asserted-by":"publisher","first-page":"20565","DOI":"10.1073\/pnas.1012865107","article-title":"CXCR4 nanobodies (VHH-based single variable domains) potently inhibit chemotaxis and HIV-1 replication and mobilize stem cells","volume":"107","author":"J\u00e4hnichen","year":"2010","journal-title":"Proc Natl Acad Sci USA."},{"key":"B41","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1021\/acsinfecdis.6b00189","article-title":"Unravelling the molecular basis of high affinity nanobodies against HIV p24: in vitro functional, structural, in silico insights","volume":"3","author":"Gray","year":"2017","journal-title":"ACS Infect Dis."},{"key":"B42","doi-asserted-by":"publisher","first-page":"e0004902","DOI":"10.1371\/journal.pntd.0004902","article-title":"Post-exposure treatment with anti-rabies VHH and vaccine significantly improves protection of mice from lethal rabies infection","volume":"10","author":"Terryn","year":"2016","journal-title":"PLoS Neglect Trop D"},{"key":"B43","doi-asserted-by":"publisher","first-page":"e0162351","DOI":"10.1371\/journal.pone.0162351","article-title":"Anti-VP6 VHH: an experimental treatment for rotavirus A-associated disease","volume":"11","author":"Maffey","year":"2016","journal-title":"PLoS ONE"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1093\/infdis\/jiq168","article-title":"Nanobodies with in vitro neutralizing activity protect mice against H5N1 influenza virus infection","volume":"203","author":"Ibanez","year":"2011","journal-title":"J Infect Dis."},{"key":"B45","doi-asserted-by":"publisher","first-page":"14158","DOI":"10.1038\/ncomms14158","article-title":"Potent single-domain antibodies that arrest respiratory syncytial virus fusion protein in its prefusion state","volume":"8","author":"Rossey","year":"2017","journal-title":"Nat Commun."},{"key":"B46","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1128\/AAC.01802-15","article-title":"Generation and characterization of ALX-0171, a potent novel therapeutic nanobody for the treatment of respiratory syncytial virus infection","volume":"60","author":"Detalle","year":"2016","journal-title":"Antimicrob Agents Chemother."},{"key":"B47","doi-asserted-by":"publisher","first-page":"eaas9667","DOI":"10.1126\/sciadv.aas9667","article-title":"Chimeric camel\/human heavy-chain antibodies protect against MERS-CoV infection","volume":"4","author":"Stalin Raj","year":"2018","journal-title":"Sci Adv."},{"key":"B48","doi-asserted-by":"publisher","first-page":"e00837","DOI":"10.1128\/JVI.00837-18","article-title":"A novel nanobody targeting Middle East respiratory syndrome coronavirus (MERS-CoV) receptor-binding domain has potent cross-neutralizing activity and protective efficacy against MERS-CoV","volume":"92","author":"Zhao","year":"2018","journal-title":"J Virol."},{"key":"B49","unstructured":"Research Program on COVID-19\/SARS-CoV-22020"},{"key":"B50","unstructured":"Science Minister Hails Nanobody Breakthrough at Franklin2020"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1101\/2020.04.16.045419","article-title":"Synthetic nanobodies targeting the SARS-CoV-2 receptor-binding domain","author":"Walter","year":"2020","journal-title":"BioRxiv [Preprint]."},{"key":"B52","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/s41592-019-0389-8","article-title":"Engineered peptide barcodes for in-depth analyses of binding protein libraries","volume":"16","author":"Egloff","year":"2019","journal-title":"Nat Methods."},{"key":"B53","unstructured":"Beroni Group and Tianjin University Have Made a Significant Discovery in Developing a Medical Solution Using Nanobody Technology for the Novel Coronavirus2020"},{"key":"B54","doi-asserted-by":"publisher","first-page":"166","DOI":"10.3390\/v11020166","article-title":"Enhanced ability of oligomeric nanobodies targeting MERS coronavirus receptor-binding domain","volume":"11","author":"He","year":"2019","journal-title":"Viruses"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.01531\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T07:39:23Z","timestamp":1592897963000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.01531\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,23]]},"references-count":54,"alternative-id":["10.3389\/fimmu.2020.01531"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.01531","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,23]]},"article-number":"1531"}}